← Leaderboards
Matthew Wayne Johnson
Johns Hopkins University
$11,865,009
Attributed
$12,351,993
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2009–24$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$12,351,993 · 11
By mechanism
R01$6,127,687 · 4
U01$3,972,165 · 1
R21$2,170,141 · 5
R03$82,000 · 1
Top collaborators
- Meghan Bridgid Moran2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Jonathan E Golub$18,054,199
- Kenneth Silverman$32,204,721
- Mary E McCaul$21,975,059
- Gary S Wand$18,956,510
- Roland R Griffiths$16,635,405
Others in their field
Top investigators on “Participant”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$407,724,307
- Lawrence Corey · Fred Hutchinson Cancer Center$333,313,234
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Albert Lazzarini · California Institute Of Technology$300,431,866
Research focus
ParticipantPharmaceutical PreparationsBaseResponseRandomizedBehavioralFutureAbstinenceGrantDiscountingDoseBehaviorPatient Self-ReportCocainePlacebosCognitiveInnovationPublic Health Medicine (Field)Double-Blind MethodRewardsPublic Health RelevanceDrug AddictionDrug AbuseAnimals
Grant awards (27)
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder$927,912
U01 · FY2024 · DA · contact PI
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder$1,544,813
U01 · FY2022 · DA · contact PI
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder$1,499,440
U01 · FY2021 · DA · contact PI
Greenwashing cigarettes: Perceptual and behavioral evidence of inaccurate modified risk advertising$482,717
R01 · FY2021 · DA
Greenwashing cigarettes: Perceptual and behavioral evidence of inaccurate modified risk advertising$491,252
R01 · FY2020 · DA
Dose effects of nicotine: Behavioral economics of cigarette abuse liability$651,831
R01 · FY2018 · DA · contact PI
Development of a Prospective Memory Intervention to Reduce Drug Use and HIV Risk$1
R01 · FY2018 · DA · contact PI
Dose effects of nicotine: Behavioral economics of cigarette abuse liability$726,049
R01 · FY2017 · DA · contact PI
Development of a Prospective Memory Intervention to Reduce Drug Use and HIV Risk$504,653
R01 · FY2017 · DA · contact PI
Dose effects of nicotine: Behavioral economics of cigarette abuse liability$767,206
R01 · FY2016 · DA · contact PI
Development of a Prospective Memory Intervention to Reduce Drug Use and HIV Risk$492,113
R01 · FY2016 · DA · contact PI
Effects of Oxytocin on the Human Abuse Liability of Methamphetamine$200,475
R21 · FY2016 · DA · contact PI
Effects of Oxytocin on the Human Abuse Liability of Methamphetamine$243,000
R21 · FY2015 · DA · contact PI
Development of a Prospective Memory Intervention to Reduce Drug Use and HIV Risk$504,653
R01 · FY2014 · DA · contact PI
Role of delay discounting in driving HIV sexual risk behavior in cocaine abuse$324,000
R01 · FY2014 · DA · contact PI
Cognitive Training in Adolescents during Treatment for Substance Use Disorders$184,606
R21 · FY2014 · DA · contact PI
Development of a Prospective Memory Intervention to Reduce Drug Use and HIV Risk$548,172
R01 · FY2013 · DA · contact PI
Role of delay discounting in driving HIV sexual risk behavior in cocaine abuse$311,040
R01 · FY2013 · DA · contact PI
Cognitive Training in Adolescents during Treatment for Substance Use Disorders$231,085
R21 · FY2013 · DA · contact PI
HIV Sexual Risk Behavior: Methamphetamine and Delay Discounting of Sexual Rewards$175,275
R21 · FY2013 · DA · contact PI
Role of delay discounting in driving HIV sexual risk behavior in cocaine abuse$324,000
R01 · FY2012 · DA · contact PI
HIV Sexual Risk Behavior: Methamphetamine and Delay Discounting of Sexual Rewards$233,700
R21 · FY2012 · DA · contact PI
Pharmacotherapy for Cocaine Dependence: d-cycloserine with Contingency Management$205,000
R21 · FY2012 · DA · contact PI
Pharmacotherapy for Cocaine Dependence: d-cycloserine with Contingency Management$246,000
R21 · FY2011 · DA · contact PI
Sexual HIV Risk Behavior and Impulsive Decision Making in Cocaine Dependence$205,000
R21 · FY2010 · DA · contact PI
Sexual HIV Risk Behavior and Impulsive Decision Making in Cocaine Dependence$246,000
R21 · FY2009 · DA · contact PI
Development of a Novel Trial-by-Trial Consequence Human Delay Discounting Task$82,000
R03 · FY2009 · DA · contact PI